Nektar Therapeutics stock initiated with buy rating at TD Cowen By Investing.com

TD Cowen initiated coverage of Nektar Therapeutics (NKTR) with a Buy and an NPV-based price target implying $109 per share, while Oppenheimer raised its target to $140 from $115; NKTR trades at $72.21 near its 52-week high of $77 after a 429% gain over the past year. The firm highlights Rezpeg (IL-2 agonist) Phase 2 data as compelling and models combined pipeline sales exceeding $6 billion. Nektar reported Q4 2025 cash of $245.8M and boosted liquidity to ~ $720M via a public offering and financings, despite a full-year net loss.

Analysis

NKTR sits at the intersection of binary clinical risk and convex upside; the market is currently pricing a high-probability commercialization outcome into a single-asset story. That creates steep sensitivity to any upcoming clinical/regulatory readouts and to early commercial signals (pricing discussions, formulary feedback, manufacturing scale), so upside can compress rapidly on one negative datapoint while positives compound returns non-linearly.

Second-order winners include emerging contract manufacturers capable of biologic scale-up and boutique commercial partners that can secure narrow formularies quickly; losers include incumbent high-priced therapies whose share could be chipped away in narrow indications if payers accept a differentiated mechanism. On the financing front, a biotech with recent capital raises reduces near-term dilution risk but increases the incentive to accelerate partnering or out-license for broader indications — expect deal activity or M&A chatter in the 6–18 month window.

Key risks: regulatory setbacks, slower-than-expected payer uptake, and manufacturing bottlenecks that shift economics materially; these are 1–12 month execution risks, while real-world adoption and peak-sales realization is a 3–7 year story. Market positioning is momentum-driven; a rotation out of small-cap biotech could create a 30–60% downside within weeks irrespective of long-term promise, so time horizon and liquidity need to be explicit when sizing exposure.

Contrarian angle: current optimism likely overweights Phase-level signals and underweights pricing friction and competitive uptake. If you require >$3–5B peak sales to justify current multiples, triage scenarios where pricing is 30–60% below assumptions and show how sensitive net present value is to launch sequencing and rebate tiers.

Key Decisions for Investors

• Small asymmetric play: Buy NKTR 9–12 month calls 40–60% OTM sized at 1–2% of portfolio — upside is multi-bagger if catalysts print; downside limited to premium (expect >60% loss of option premium if no positive catalyst).
• Hedged equity exposure: Buy NKTR stock with simultaneous purchase of 6–12 month puts 30–40% OTM (collar financing optional) — reduces tail risk from a sudden clinical/regulatory miss while retaining upside; target net cost <2% of position value.
• Event-driven pair: Long NKTR equity vs short XBI (equal dollar) for 3–6 months to isolate idiosyncratic readout risk — this converts a directional biotech bet into an alpha-seeking trade vs sector beta; if NKTR outperforms sector by >25% capture profits.
• Liquidity/exit plan: Scale initial exposure to no more than 3% of strategy AUM, set stop-loss at 30% drawdown from entry for unhedged positions, and schedule re-evaluation at each major clinical/regulatory milestone (30–90 day cadence).